AstraZeneca Plans To Set Up Separate Division For Vaccines & Antibody Therapies - ReportBenzinga • 11/10/21
Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology TherapeuticsPRNewsWire • 11/03/21
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric CancerBusiness Wire • 11/03/21
AstraZeneca's premium growth story still not appreciated by the market, leading investment bank saysProactive Investors • 11/02/21
Will LogicBio Therapeutics (LOGC) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 11/01/21
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health DisparitiesBusiness Wire • 11/01/21
AstraZeneca's Imfinzi/Chemo Combo Strikes First Immunotherapy Wins In Bile Duct Cancer TrialBenzinga • 10/26/21
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung CancerBusiness Wire • 10/25/21
AstraZeneca posts stellar late-stage trial results for advanced biliary tract cancer candidateProactive Investors • 10/25/21